How to Open Your FREE DEMAT Account
The Indian pharmaceutical industry has emerged as a global leader in generic drug manufacturing, benefiting significantly from the expiry of patents on several blockbuster drugs worldwide. This advantage has allowed Indian companies to supply cost-effective alternatives to international markets, driving strong export-led growth. The industry is set for robust expansion, with annual revenue projected to reach ₹7,327 Bn by FY30, reflecting a CAGR of 10% during FY25-30. Furthermore, strategic acquisitions, global partnerships, and adherence to stringent international quality standards have strengthened the global presence of Indian pharmaceutical firms, positioning them well to capitalize on rising demand across key markets.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing (i) high purity advance pharmaceutical intermediates (“Pharma Intermediates”) which serve as raw material/key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (“APIs”) which serve as raw material for pharmaceutical formulations in preparation of various types of Finished Dosage Formula (“FDF”) such as tablets, capsules, ointments, syrups, as well as ingredients in nutraceutical formulations, personal care products and animal health products. The Company’s product portfolio spans pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs, and ingredients for personal care and veterinary API. Its API products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP.
Anlon Healthcare has delivered a strong financial performance over the period, with revenue from operations rising to ₹1202.87 million in FY25 from ₹1128.77 million in FY23, reflecting steady growth despite industry challenges. EBITDA more than doubled from ₹124.15 million in FY23 to ₹322.09 million in FY25, with margins expanding significantly from 11% to 26.78%. Net profit also surged from ₹58.2 million in FY23 to ₹205.18 million in FY25, driving PAT margins higher from 5.16% to 17.06%. Return ratios remained healthy, with ROE at 25.51% and ROCE at 21.93% in FY25, underscoring efficient capital utilization. Importantly, the company has strengthened its balance sheet, with debt-equity improving sharply from 9.00 in FY23 to 0.73 in FY25, highlighting improved financial stability and reduced leverage.
Objects of the Issue:
- Funding capex requirements – INR 307.20 million
- Prepayment or repayment of borrowings – INR 50 million
- Funding Working Capital requirements – INR 431.5 million
- General corporate purposes
📱 Apply Online through the SMIFS ELITE App | Download now:
Experience seamless investing at your fingertips!
